# Truist Securities

Type: Company

Source: Finance Intelligence Brief — https://getfinancebrief.com/entity/truist-securities-company
Canonical HTML page: https://getfinancebrief.com/entity/truist-securities-company

## Timeline

- **2026-03-15**: Eventide Rebalancing — Eventide Asset Management reports a reduced but significant stake of $83.65 million in Collegium.
- **2026-03-06**: Institutional Reduction — Integrated Quantitative Investments LLC reduces its stock position in COLL.
- **2026-02-18**: Truist Analysis — Truist Securities highlights momentum for Jornay PM and a robust pain portfolio.
- **2022-03-22**: BDSI Acquisition — Collegium completes the acquisition of BioDelivery Sciences International, adding Belbuca to its portfolio.

## Recent coverage (2 stories)

### Truist Adjusts Community Healthcare Trust Target Amid Growth Optimism
2026-03-19 07:39:13 · Sentiment: Neutral · Impact: 5/10 · Sources: 2

Truist Securities has lowered its price target for Community Healthcare Trust (CHCT) while maintaining a positive outlook on the company's long-term growth trajectory. The adjustment follows a recent earnings miss but underscores confidence in the REIT's specialized non-urban healthcare portfolio.
Full story: https://getfinancebrief.com/story/truist-cuts-chct-target-growth-view

### Eventide Asset Management Trims Stake in Collegium Pharmaceutical to $83.6M
2026-03-15 12:47:55 · Sentiment: Neutral · Impact: 5/10 · Sources: 2

Eventide Asset Management LLC has reduced its equity position in Collegium Pharmaceutical, Inc. (COLL), though it maintains a significant $83.65 million stake. This institutional shift comes as the specialty pharmaceutical firm navigates a shifting landscape for chronic pain management and expands into neurology.
Full story: https://getfinancebrief.com/story/eventide-reduces-collegium-pharmaceutical-stake

---
This page is a machine-readable summary. Sentiment measures the directional read of each development for this entity, not the tone of the reporting; impact weights consequence, not syndication reach. See https://getfinancebrief.com/guides/methodology for the full editorial methodology.